Mesoblast (MESO) Income from Non-Controlling Interests (2016 - 2021)
Mesoblast (MESO) posted quarterly Income from Non-Controlling Interests of $278000.0 for Q4 2021, down 67.33% year-on-year from $851000.0 in Q4 2020, and up 242.56% on a QoQ basis from -$195000.0 in Q3 2021.
Mesoblast (MESO) Income from Non-Controlling Interests (2016 - 2021) Analysis & Trends
Mesoblast (MESO) has reported Income from Non-Controlling Interests for 6 consecutive years, with $278000.0 the latest figure, recorded in Q4 2021.
- Quarterly Income from Non-Controlling Interests fell 67.33% year-over-year to $278000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $1.4 million (up 30.91% YoY) and the FY2022 annual result came in at -$231000.0, up 82.43% from the prior year.
- Income from Non-Controlling Interests grew to $278000.0 in Q4 2021 per MESO's latest filing, from -$195000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for MESO reached as high as $851000.0 in Q4 2020 and fell as low as -$338000.0 in Q3 2017.
- A 5-year average of $79444.4 and a median of $34000.0 in 2017 frame the typical range for Income from Non-Controlling Interests.
- The largest YoY upside for Income from Non-Controlling Interests was 118.93% in 2018 against a maximum downside of 544.12% in 2018.
- Year by year, Income from Non-Controlling Interests stood at -$338000.0 in 2017, then jumped by 118.93% to $64000.0 in 2018, then plunged by 595.31% to -$317000.0 in 2019, then surged by 368.45% to $851000.0 in 2020, then plunged by 67.33% to $278000.0 in 2021.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $278000.0, -$195000.0, and $851000.0 for Q4 2021, Q3 2021, and Q4 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 278,000.00 |
| Sep 30, 2021 | -195,000.00 |
| Dec 31, 2020 | 851,000.00 |
| Sep 30, 2020 | 489,000.00 |
| Jun 30, 2019 | -317,000.00 |
| Sep 30, 2018 | 64,000.00 |
| Jun 30, 2018 | -151,000.00 |
| Sep 30, 2017 | -338,000.00 |
| Jun 30, 2017 | 34,000.00 |
| Jun 30, 2016 | -567,000.00 |